NASDAQ:AVRO AVROBIO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AVROBIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.92 -0.09 (-8.91%) (As of 06/30/2022 05:48 PM ET) Add Compare Share Today's Range$0.92▼$1.0050-Day Range$0.75▼$1.0752-Week Range$0.74▼$9.37Volume309,224 shsAverage Volume666,584 shsMarket Capitalization$40.20 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address AVRO Stock Forecast (MarketRank)Overall MarketRank™2.16 out of 5 starsMedical Sector432nd out of 1,433 stocksBiological Products, Except Diagnostic Industry72nd out of 217 stocksAnalyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 - 3.3 Analyst's Opinion Consensus RatingAVROBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, AVROBIO has a forecasted upside of 705.1% from its current price of $0.93.Amount of Analyst CoverageAVROBIO has received no research coverage in the past 90 days. Previous Next 4.5 Community Rank Outperform VotesAVROBIO has received 170 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAVROBIO has received 82 “underperform” votes. (Add your “underperform” vote.)Community SentimentAVROBIO has received 67.46% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about AVROBIO and other stocks. Vote “Outperform” if you believe AVRO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AVRO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAVROBIO does not currently pay a dividend.Dividend GrowthAVROBIO does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AVROBIO insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of AVROBIO is held by insiders.Percentage Held by Institutions63.92% of the stock of AVROBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for AVROBIO are expected to grow in the coming year, from ($2.14) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AVROBIO is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AVROBIO is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAVROBIO has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AVROBIO (NASDAQ:AVRO)AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More AVRO Stock News HeadlinesJune 23, 2022 | americanbankingnews.comAVROBIO, Inc. (NASDAQ:AVRO) Receives Average Rating of "Moderate Buy" from AnalystsJune 16, 2022 | seekingalpha.comBioLineRx hires Avrobio exec as chief commercial officer to bolster cancer therapy efforts - Seeking AlphaJune 11, 2022 | seekingalpha.comWith bluebird bio's success, what are other gene therapies companies to pay attention to? - Seeking AlphaJune 5, 2022 | americanbankingnews.com Brokerages Anticipate AVROBIO, Inc. (NASDAQ:AVRO) to Announce -$0.54 Earnings Per ShareMay 19, 2022 | nasdaq.comWhat Is The Relative Strength Index (RSI) In Stocks? - NasdaqMay 18, 2022 | nasdaq.comInvestors Heavily Search Chevron Corporation (CVX): Here is What You Need to Know - NasdaqMay 18, 2022 | finance.yahoo.comHospital Privacy Screens Market Size & Share [2022-2029] | Industry Analysis, Growth, Trends, Revenue by Fortune Business Insights - Yahoo FinanceMay 18, 2022 | businesswire.comAVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Business WireMay 18, 2022 | finance.yahoo.comAVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual MeetingMay 17, 2022 | marketwatch.comAvrobio Shares Rise on Encouraging Clinical Trial Data - MarketWatchMay 17, 2022 | finance.yahoo.comAVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy StudyMay 17, 2022 | finance.yahoo.comAVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures - Yahoo FinanceMay 17, 2022 | finance.yahoo.comAVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive MeasuresSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVRO CUSIPN/A CIK1681087 Webwww.avrobio.com Phone(617) 914-8420FaxN/AEmployees122Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today6/30/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$7.50 High Stock Price Forecast$23.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+715.2%Consensus RatingModerate Buy Rating Score (0-4)2.66666666666667 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119.13 million Net MarginsN/A Pretax MarginN/A Return on Equity-67.14% Return on Assets-58.56% Debt Debt-to-Equity Ratio0.10 Current Ratio9.98 Quick Ratio9.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.88 per share Price / Book0.24Miscellaneous Outstanding Shares43,696,000Free Float40,899,000Market Cap$40.20 million OptionableNot Optionable Beta1.72 AVROBIO Frequently Asked Questions Should I buy or sell AVROBIO stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AVROBIO stock. View analyst ratings for AVROBIO or view top-rated stocks. What is AVROBIO's stock price forecast for 2022? 6 equities research analysts have issued twelve-month target prices for AVROBIO's stock. Their AVRO stock forecasts range from $3.00 to $23.00. On average, they predict AVROBIO's share price to reach $7.50 in the next year. This suggests a possible upside of 715.2% from the stock's current price. View analysts' price targets for AVROBIO or view top-rated stocks among Wall Street analysts. How has AVROBIO's stock price performed in 2022? AVROBIO's stock was trading at $3.85 at the beginning of 2022. Since then, AVRO shares have decreased by 76.1% and is now trading at $0.92. View the best growth stocks for 2022 here. When is AVROBIO's next earnings date? AVROBIO is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for AVROBIO. How were AVROBIO's earnings last quarter? AVROBIO, Inc. (NASDAQ:AVRO) posted its earnings results on Tuesday, May, 10th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $0.10. View AVROBIO's earnings history. Who are AVROBIO's key executives? AVROBIO's management team includes the following people: Mr. Geoff MacKay BSc, Co- Founder, Pres, CEO & Director (Age 56, Pay $754.39k)Mr. Erik John Ostrowski M.B.A., CFO & Treasurer (Age 49, Pay $554.66k)Dr. Christopher Mason FMEDSCI, FRCS, M.D., Ph.D., Chief Scientific Officer (Age 63, Pay $521.28k)Mr. Jeffrey Medin Ph.D., Scientific FounderMr. Matthew Arnold, Head of OperationsMr. Steven N. Avruch J.D., Chief Legal Officer & Sec. (Age 61)Ms. Monique Da Silva, Sr. VP of Corp. CommunicationsMs. Deanna M. Petersen MBA, Chief Bus. Officer (Age 60)Ms. Holly May, Chief Commercial OfficerMr. Kim Raineri M.B.A., Chief Manufacturing & Technical Operations Officer Who are some of AVROBIO's key competitors? Some companies that are related to AVROBIO include Genfit (GNFT), Ikena Oncology (IKNA), Graphite Bio (GRPH), INmune Bio (INMB), Jounce Therapeutics (JNCE), ARYA Sciences Acquisition Corp IV (ARYD), Taysha Gene Therapies (TSHA), Fennec Pharmaceuticals (FENC), Armata Pharmaceuticals (ARMP), Finch Therapeutics Group (FNCH), Cellectis (CLLS), Passage Bio (PASG), Genenta Science (GNTA), Compugen (CGEN) and Big Cypress Acquisition (BCYP). View all of AVRO's competitors. What other stocks do shareholders of AVROBIO own? Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven Pharmaceutical (BHVN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS). When did AVROBIO IPO? (AVRO) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager. What is AVROBIO's stock symbol? AVROBIO trades on the NASDAQ under the ticker symbol "AVRO." How do I buy shares of AVROBIO? Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AVROBIO's stock price today? One share of AVRO stock can currently be purchased for approximately $0.92. How much money does AVROBIO make? AVROBIO (NASDAQ:AVRO) has a market capitalization of $40.20 million. The company earns $-119.13 million in net income (profit) each year or ($2.82) on an earnings per share basis. How many employees does AVROBIO have? AVROBIO employs 122 workers across the globe. How can I contact AVROBIO? AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The official website for AVROBIO is www.avrobio.com. The company can be reached via phone at (617) 914-8420 or via email at [email protected]. This page (NASDAQ:AVRO) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
